Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy

Abstract

: This review is focused on the healing of fistulas and stable gastric pentadecapeptide BPC 157. Assuming that the healing of the various wounds is essential also for the gastrointestinal fistulas healing, the healing effect on fistulas in rats, consistently noted with the stable gastric pentadecapeptide BPC 157, may raise several interesting possibilities. BPC 157 is originally an anti-ulcer agent, native to and stable in human gastric juice (for more than 24 h). Likely, it is a novel mediator of Robert’s cytoprotection maintaining gastrointestinal mucosal integrity. Namely, it is effective in the whole gastrointestinal tract, and heals various wounds (i.e., skin, muscle, tendon, ligament, bone; ulcers in the entire gastrointestinal tract; corneal ulcer); LD1 is not achieved. It is used in ulcerative colitis clinical trials, and now in multiple sclerosis, and addressed in several reviews. Therefore, it is not surprising that BPC 157 has documented consistent healing of the various gastrointestinal fistulas, external (esophagocutaneous, gastrocutaneous, duodenocutaneous, colocutaneous) and internal (colovesical, rectovaginal). Taking fistulas as a pathological connection, this rescue is verified with the beneficial effects in rats with the various gastrointestinal anastomoses, esophagogastric, jejunoileal, colo-colonic, ileoileal, esophagojejunal, esophagoduodenal, and gastrojejunal. This beneficial effect occurs equally when the gastrointestinal anastomoses are impaired with the application of NSAIDs, cysteamine, large bowel resection, as well as concomitant esophageal, gastric, and duodenal lesions and/or ulcerative colitis presentation, short bowel syndrome progression, liver and brain disturbances presentation. Particular aspects of the BPC 157 healing of the fistulas are especially emphasized.

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

“…Consequently, we hold fistulas commonality (Klicek et al, 2008;Skorjanec et al, 2009;Cesarec et al, 2013;Skorjanec et al, 2015;Baric et al, 2016;Grgic et al, 2016;Sikiric et al, 2020a) and thereby, the revealing common resolution (Sikiric et al, 2020a). There are two different tissues simultaneously affected and a healing process that would organize synchronized healing (Sikiric et al, 2020a).…”

“…Consequently, we hold fistulas commonality (Klicek et al, 2008;Skorjanec et al, 2009;Cesarec et al, 2013;Skorjanec et al, 2015;Baric et al, 2016;Grgic et al, 2016;Sikiric et al, 2020a) and thereby, the revealing common resolution (Sikiric et al, 2020a). There are two different tissues simultaneously affected and a healing process that would organize synchronized healing (Sikiric et al, 2020a). Thus, the main implication of the fistula healing model as wounds with abnormal connections is the verification of the effectiveness of the skin wound healing as understood with BPC 157 effects in the skin wound models (Seiwerth et al, 1997;Mikus et al, 2001;Sikiric et al, 2003;Xue et al, 2004a;Bilic et al, 2005;Seveljevic-Jaran et al, 2006;Tkalcevic et al, 2007;Huang et al, 2015).…”

“…Almost no arterial clots (HE,x4 (b), x10 (B)) were observed. Gwyer et al, 2019;Park et al, 2020;Sikiric et al, 2020a;Sikiric et al, 2020b). Contrarily, when there is a peptide carrier, far more investigated and commonly implied angiogenic standard growth factors in the growth factor healing concept (Tarnawski and Ahluwalia, 2012;Deng et al, 2013) have several limitations (i.e., local application, carrier addition, and weak and uncertain peptide activity of its own (Seiwerth et al, 2018)), delaying practical realization of the growth factor healing concept.…”

“…Of note, the methodology of this healing evidence (Klicek et al, 2008;Skorjanec et al, 2009;Cesarec et al, 2013;Skorjanec et al, 2015;Baric et al, 2016;Grgic et al, 2016;Sikiric et al, 2020a) may contrast with the miscellaneous underlying fistula causes, various origin and location and different occurrences (Orangio, 2010;Visschers et al, 2012;Tonolini and Magistrelli, 2017). Likewise, this approach may contrast with therapeutic tactics for fistulas, which depend on their location and severity of occurrence (Orangio, 2010;Visschers et al, 2012;Tonolini and Magistrelli, 2017).…”

“…Also, it opposes the nowadays aggressive wound management if it considers in fistulas healing mostly local skin protection (Orangio, 2010;Visschers et al, 2012;Tonolini and Magistrelli, 2017). On the other hand, this healing evidence as such (Klicek et al, 2008;Skorjanec et al, 2009;Cesarec et al, 2013;Skorjanec et al, 2015;Baric et al, 2016;Grgic et al, 2016;Sikiric et al, 2020a) may accommodate and resolve the mentioned fistula diversity (Orangio, 2010;Visschers et al, 2012;Tonolini and Magistrelli, 2017) as a common healing denominator providing simultaneous healing of different tissues.…”